Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Prime Medicine, Inc.
NASDAQ:PRMEHealthcare · Biotechnology
-9.92%$4.72
AH$4.70-0.33%vs close
Mkt Cap$856.1M
Float95.66M
O/S181.38M
Vol
$ Vol
RVOL
Inst Own59.2%
SI34.4%
Earnings
Dilution
Financials Summary
Revenue$4.63M
Net Income-$201.14M
Total Assets$342.73M
Free Cash Flow-$167.09M
Debt & Equity
Debt 49%
Equity 51%
Total Debt$116.43M
Total Equity$120.87M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PRME's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$342.73M
Liabilities$221.87M
Accounts Receivable$0
Accounts Payable$8.89M
Inventory$0
PP&E (Net)$146.75M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $4.63M | $2.98M | $0 | $0 | $0 | $5.21M | $0 |
| YoY Growth | 55.3% | - | - | - | - | - | - |
| Cost of Revenue | $7.32M | $0 | $0 | $0 | $0 | $2.98M | $2.76M |
| Gross Profit | -$2.69M | $2.98M | $0 | $0 | $0 | $2.23M | -$2.76M |
| Gross Margin | -58.1% | 100.0% | - | - | - | 42.8% | - |
| Research and Development | $160.64M | $155.29M | $147.91M | $86.72M | $70.55M | $2.98M | $920K |
| Selling, General, and Administrative | $52.35M | $50.16M | $43.39M | $29.82M | $13.92M | $3.16M | $1.25M |
| Other | -$7.32M | $0 | $13.5M | $0 | $0 | -$2.98M | $0 |
| Total Operating Expenses | $205.66M | $205.45M | $204.79M | $116.54M | $84.47M | $3.16M | $2.17M |
| Operating Income (EBIT) | -$208.35M | -$202.47M | -$204.79M | -$116.54M | -$84.47M | -$932K | -$2.17M |
| Operating Margin | -4498.1% | -6787.4% | - | - | - | -17.9% | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $4.15M | $3.52M | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $7.21M | $6.58M | $6.38M | -$6.22M | -$81.38M | -$611K | $0 |
| Income Before Tax (EBT) | -$201.14M | -$195.88M | -$198.41M | -$122.77M | -$165.85M | -$1.54M | -$2.52M |
| Income Tax Expense | $0 | $0 | -$279K | -$948K | -$486K | $1.87M | $4K |
| Net Income | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -$165.37M | -$3.41M | -$2.53M |
| Net Income Margin | -4342.4% | -6566.6% | - | - | - | -65.5% | - |
| Supplementary Data | |||||||
| EPS | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Diluted EPS | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Weighted Average OS | 148.76M | 118.60M | 90.97M | 97.21M | 95.73M | 95.73M | 95.73M |
| EBITDA | -$195.76M | -$189.75M | -$186.64M | -$120.55M | -$165.28M | -$889K | $3.99M |
| EBITDA Margin | -4226.2% | -6361.2% | - | - | - | -17.1% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $63.03M | $182.48M | $41.57M | $187.62M | $185.42M | $36.98M | $8.65M |
| Short-Term Investments | $114.65M | $7.97M | $80.09M | $106.3M | $84.2M | $16.35M | $0 |
| Cash and Short-Term Investments | $177.68M | $190.44M | $121.67M | $293.92M | $269.62M | $53.33M | $8.65M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.61M | $14.67M | $2.25M | $246K | $0 | $0 | $50K |
| Total Current Assets | $181.29M | $211.89M | $142.98M | $296.62M | $270.58M | $53.4M | $8.7M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $146.75M | $71.56M | $36.6M | $48.55M | $15.68M | $596K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $14.69M | $14.06M | $14.28M | $15.14M | $15.6M | $785K | $0 |
| Total Long-Term Assets | $161.44M | $85.62M | $50.88M | $63.7M | $31.28M | $1.38M | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $342.73M | $297.51M | $193.85M | $360.31M | $301.86M | $54.78M | $8.7M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $8.89M | $11.35M | $19.54M | $4.33M | $1.44M | $250K | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $7.82M | $7.09M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $9.04M | $6.93M | $10.91M | $6.98M | $14.66M | $19.08M | $7.31M |
| Total Current Liabilities | $37.45M | $37.96M | $56.42M | $26.71M | $57.98M | $19.44M | $7.31M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $108.29M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $63.22M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $279K | $1.24M | $1.87M | $0 |
| Other Long-Term Liabilities | $76.13M | $6M | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $184.42M | $106.4M | $4.36M | $17.33M | $4.31M | $1.87M | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $221.87M | $144.36M | $60.78M | $44.04M | $62.3M | $21.31M | $7.31M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $395.8M | $31.14M | $3.99M |
| Common Stock | $2K | $2K | $2K | $2K | $1K | $0 | $1K |
| Retained Earnings | -$888.35M | -$687.21M | -$491.33M | -$293.2M | -$171.38M | -$6.01M | -$2.6M |
| Comprehensive Income & Other | $82K | $1K | -$15K | -$384K | -$27K | $0 | $0 |
| Other Stockholders' Equity | $1.01B | $840.36M | $624.4M | $609.47M | $410.94M | $39.48M | $3.99M |
| Total Equity | $120.87M | $153.15M | $133.07M | $316.27M | $239.56M | $33.47M | $1.39M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $342.73M | $297.51M | $193.85M | $360.31M | $301.86M | $54.78M | $8.7M |
| Supplementary Data | |||||||
| Total Debt | $116.43M | $40.79M | $13.63M | $28.75M | $10.41M | $0 | $0 |
| Net Debt | $53.4M | -$141.68M | -$27.94M | -$158.88M | -$175.01M | -$36.98M | -$8.65M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -$165.37M | -$3.41M | -$2.53M |
| Depreciation & Amortization | $5.38M | $6.13M | $4.65M | $2.22M | $568K | $43K | $6.52M |
| Deferred Income Tax | $0 | $0 | -$279K | -$964K | -$624K | $1.87M | $0 |
| Stock-Based Compensation | $29.27M | $26.07M | $13.91M | $6.46M | $1.75M | $391K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $996K | -$5.26M | $9.14M | $2.46M | $1.19M | $250K | $0 |
| Other Working Capital | -$6.34M | $36.33M | -$6.49M | -$37.86M | $29.99M | -$86K | $492K |
| Total Working Capital Change | -$5.34M | $31.08M | $2.65M | -$35.4M | $31.18M | $164K | $492K |
| Other Non-Cash Items | $9.27M | $9.74M | $11.79M | $17.68M | $98.42M | -$4.6M | -$5.81M |
| Net Cash from Operating | -$162.56M | -$122.86M | -$165.41M | -$131.83M | -$34.08M | -$5.54M | -$1.33M |
| Investing Activities | |||||||
| Capital Expenditures | -$4.53M | -$7.29M | -$8.72M | -$16.09M | -$4.15M | -$639K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$205.41M | -$129.45M | -$104.95M | -$123.34M | -$81.98M | $0 | $0 |
| Sales of Investments | $101.18M | $204.2M | $132.56M | $93M | $13M | $0 | $0 |
| Other Investing Activities | $0 | $1M | -$170K | -$665K | -$496K | -$423K | $0 |
| Net Cash from Investing | -$108.76M | $68.46M | $18.71M | -$47.1M | -$73.63M | -$1.06M | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $139.51M | $170.14M | $655K | $185.32M | $270.36M | $0 | $9.98M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $12M | $25.74M | $0 | -$3.82M | -$1.09M | -$20K | $0 |
| Net Cash from Financing | $151.51M | $195.88M | $655K | $181.49M | $269.28M | $34.93M | $9.98M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | -$8.65M |
| Net Change in Cash | -$119.81M | $141.47M | -$146.05M | $2.57M | $161.57M | $28.33M | $0 |
| Supplementary Data | |||||||
| Operating Cash Flow | -$162.56M | -$122.86M | -$165.41M | -$131.83M | -$34.08M | -$5.54M | -$1.33M |
| Capital Expenditure | -$4.53M | -$7.29M | -$8.72M | -$16.09M | -$4.15M | -$639K | $0 |
| Free Cash Flow | -$167.09M | -$130.16M | -$174.14M | -$147.92M | -$38.23M | -$6.18M | -$1.33M |
| Cash at Beginning | $196.54M | $55.07M | $201.12M | $198.54M | $36.98M | $8.65M | $0 |
| Cash at End | $76.72M | $196.54M | $55.07M | $201.12M | $198.54M | $36.98M | $0 |